INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
INO$1.45-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| Preferred stock · Common stock · Additionalpaid-incapital · Accumulateddeficit · Accumulatedothercomprehensiveloss · Totalstockholders’equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Numberof shares · Amount · Numberof shares · Amount | |||||||||
| Balance at December 31, 2022 | 9 | $— | 21,090,938 | $21,090 | $1,710,888,191 | $(1,487,847,784) | $(698,741) | $222,362,756 | |
| Issuance of common stock for legal settlement | — | — | 760,083 | 760 | 13,999,240 | — | — | 14,000,000 | |
| Issuance of common stock for cash, net of financing costs | — | — | 875,305 | 875 | 5,460,870 | 5,461,745 | |||
| Vesting of RSUs, net of tax payments | — | — | 66,749 | 67 | (466,713) | — | — | (466,646) | |
| Stock-based compensation | — | — | — | — | 11,072,486 | — | — | 11,072,486 | |
| Net loss | — | — | — | — | — | (135,117,352) | — | (135,117,352) | |
| Unrealized gain on short-term investments, net of tax | — | — | — | — | — | — | 40,060 | 40,060 | |
| Foreign currency translation | — | — | — | — | — | — | (3,920) | (3,920) | |
| Balance at December 31, 2023 | 9 | $— | 22,793,075 | $22,792 | $1,740,954,074 | $(1,622,965,136) | $(662,601) | $117,349,129 | |
| Issuance of common stock for cash, net of financing costs | — | $— | 13,213,778 | $13,214 | $36,020,259 | $— | $— | $36,033,473 | |
| Issuance of pre-funded warrants for cash, net of financing costs | — | — | — | — | 16,146,397 | — | — | 16,146,397 | |
| Exercise of stock options for cash and vesting of RSUs, net of tax payments | — | — | 93,138 | 93 | (353,213) | — | — | (353,120) | |
| Stock-based compensation | — | — | — | — | 6,595,108 | — | — | 6,595,108 | |
| Net loss | — | — | — | — | — | (107,254,126) | — | (107,254,126) | |
| Unrealized loss on short-term investments, net of tax | — | — | — | — | — | — | (45,469) | (45,469) | |
| Foreign currency translation | — | — | — | — | — | — | 32,403 | 32,403 | |
| Balance at December 31, 2024 | 9 | $— | 36,099,991 | $36,099 | $1,799,362,625 | $(1,730,219,262) | $(675,667) | $68,503,795 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.